Piper Jaffray analyst David Amsellem conducted a survey of 27 gastroenterologists and general practitioners who are significant prescribers of Allergan's (AGN) Linzess and have significant familiarity with Bausch Health's (BHC) recently-acquired Trulance. The feedback suggests that physicians on the whole do not perceive dramatic differences between the two agents, Amsellem tells investors in a research note. The feedback also suggested that an improved payer landscape for Trulance would drive a significantly larger volume footprint for the product, adds the analyst. He continues to believe that growing contribution from new assets are likely to drive "meaningful," longer-term EBITDA growth for Bausch Health. Amsellem reiterates an Overweight rating on the shares with a $28 price target.